MedTrace Logo

Treating Amyotrophic Lateral Sclerosis (ALS) With R(+) Pramipexole Dihydrochloride Monohydrate at 60 mg/Day

NCT00596115 · Status: TEMPORARILY_NOT_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2012-07-25

No results posted yet for this study

Summary

R(+) pramipexole dihydrochloride monohydrate \[R(+)PPX\], an experimental neuroprotective drug, is provided in this open label extension study to ALS patients who have participated in earlier clinical protocols.

Conditions

Interventions

DRUG

R(+) pramipexole dihydrochloride monohydrate

20 mg tid per day orally

Sponsors & Collaborators

  • University of Pittsburgh

    collaborator OTHER

  • University of Nebraska

    collaborator OTHER

  • Bennett, James P., Jr., M.D., Ph.D.

    lead INDIV

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00596115 on ClinicalTrials.gov